drugset / Trial / NCT01619332

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

NCT01619332

Phase 1/2 Completed 220 enrolled Novartis Pharmaceuticals
Parallel-groupQuadruple-blindTreatment

Summary

This study is a three part study to assess the safety and efficacy of LEZ763 on normal healthy volunteers and patients with Type 2 Diabetes.

Timeline

Start
2012-03
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject LEZ763 Unknown Oral
Comparator Sitagliptin Small molecule Oral